Trial
NCT04952584
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Baylor College of Medicine
Collaborators
The Methodist Hospital Research Institute
Condition
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Intervention
CD30.CAR-EBVST cells
Why stopped
Study was not activated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-07